Myomo's core business model is well defined around a high-value medical device with strong Medicare Part B reimbursement driving rapid revenue growth and improving margins. The company's differentiation lies in its specialized robotics-enabled orthoses and a growing, trained provider network, which…
Myomo (MYO) Q1 2025: Revenue Surges 162% Amid Pipeline Growth and Reimbursement Challenges
Myomo delivered robust year-over-year revenue growth driven by Medicare Part B adoption and international expansion despite temporary lead generation headwinds and insurance authorization delays. Operational investments in product innovation and channel development position the company for accelerated growth in the back half of 2025. Management reaffirmed full-year guidance, signaling confidence in overcoming reimbursement and marketing challenges.
Summary
- Medicare-Driven Revenue Expansion: Strong uptake of MyoPro devices among Medicare Part B patients underpins growth.
- Channel and Product Innovation Momentum: Expansion of orthotics and prosthetics (O&P) distribution and new product launches support future growth.
- Reimbursement and Lead Generation Challenges: Temporary marketing disruptions and high denial rates from Medicare Advantage create near-term headwinds.
Business Overview
Myomo is a wearable medical robotics company specializing in powered upper-limb orthoses designed to restore arm and hand function for patients with neurological disorders or paralysis. The company generates revenue primarily through sales of its flagship MyoPro device, with major segments including direct billing to Medicare and commercial insurers, and an expanding orthotics and prosthetics (O&P) channel. International sales, primarily in Germany, also contribute to revenue.
Performance Analysis
Myomo reported first quarter 2025 revenue of $9.8 million, a 162% increase over Q1 2024, propelled by a doubling of units sold to 182 and a 31% rise in average selling price (ASP) to approximately $54,000. Medicare Part B patients comprised 59% of revenue, reflecting the successful commercialization following Medicare coverage effective April 2024. International revenue grew 42% year-over-year to $1.3 million, representing 13% of total sales.
Despite strong top-line growth, the company faced operational headwinds as changes in Meta’s advertising algorithms temporarily disrupted lead generation early in the quarter, increasing the cost per pipeline add by 31% to $2,300. Additionally, persistent utilization management by Medicare Advantage and other commercial payers led to slower authorization rates and a 9% decline in backlog units to 249. Operating expenses rose 64% year-over-year, driven by increased payroll, research and development, and advertising spend, reflecting strategic investments funded by a recent capital raise.
- Unit Volume and ASP Growth: Revenue units doubled, with ASP rising 31% due to Medicare fee implementation and product mix.
- Pipeline Expansion Amid Lead Generation Issues: Record 700 medically qualified patients added to the pipeline, up 42%, offsetting early quarter marketing disruptions.
- Margin Improvement and Cost Pressure: Gross margin expanded to 67.2% from 61.2% due to higher ASP and fixed cost absorption, while operating losses narrowed slightly.
Overall, the quarter demonstrated strong demand and operational scaling, tempered by external reimbursement challenges and marketing disruptions, which management is actively addressing to sustain growth momentum.
Executive Commentary
"Our first quarter financial results were in line with expectations, yet several operating metrics were affected by continued utilization management by Medicare Advantage plans which impacted authorizations and orders, as well as changes to social media algorithms that disrupted lead flow and increased our cost per pipeline add during the first six weeks of the quarter. I'm pleased to report that both lead flow and pipeline adds rebounded in March and April."
Paul R. Gudonis, Chief Executive Officer
"Revenue for the first quarter of 2025 was $9.8 million. This represents a 162% increase versus the prior year quarter and was driven by a higher number of revenue units and a higher ASP. Our growth was fueled by revenues from patients with Medicare Part B coverage and international revenues."
Dave Henry, Chief Financial Officer
Strategic Positioning
1. Leveraging Medicare Part B Coverage to Drive Adoption
The one-year anniversary of Medicare Part B coverage for MyoPro has been pivotal, enabling Myomo to capture a large share of patients eligible under this reimbursement pathway. With Medicare Part B patients accounting for nearly 60% of revenue, the company’s focus on this segment supports higher velocity revenue recognition and improved gross margins. Management continues to advocate for expanded coverage and is engaging with payer medical directors to address denials.
2. Building Orthotics and Prosthetics Channel Capacity
Myomo has significantly expanded its O&P distribution channel, training over 300 certified prosthetist orthotists (CPOs) who can evaluate patients, navigate reimbursement, and place orders. The launch of the MyoPro 2X and hands-on certification classes enhance this channel’s capability to scale patient assessments and device placements, positioning it for accelerated revenue growth in the second half of 2025.
3. Product Innovation and Manufacturing Scale-Up
The company introduced two product upgrades in early 2025: the Mark II clinical evaluation device and the MyoPro 2X, which incorporate clinical feedback to improve patient independence. The recent facility move to Burlington, Massachusetts, has increased manufacturing capacity to 120 units per month, supporting anticipated demand growth and enabling future floor space expansion.
4. Navigating Marketing and Lead Generation Challenges
Changes in Meta’s algorithms disrupted lead generation early in the quarter, elevating cost per pipeline add. Myomo’s agency adapted proprietary strategies to restore and improve lead flow, yielding record pipeline additions in March and April. Sustaining this marketing efficiency is critical to filling the top of the funnel and supporting the revenue ramp planned for the year’s second half.
5. Addressing Insurance Authorization and Utilization Management
High denial rates from Medicare Advantage and commercial payers remain a significant hurdle, slowing authorization and order flow and pressuring backlog levels. The company is actively pursuing in-network contracts, appeals, and administrative law judge hearings to improve patient access. This ongoing payer engagement is essential to unlock the full market potential.
Key Considerations
Myomo’s Q1 performance reflects a complex interplay between strong underlying demand and operational headwinds, highlighting the critical importance of reimbursement and marketing execution for growth.
- Medicare Coverage as a Growth Engine: The Medicare Part B fee schedule is a key enabler of higher ASPs and unit velocity, underpinning margin improvement.
- Pipeline Quality and Conversion Dynamics: Despite record pipeline additions, conversion rates to authorizations were pressured by payer denials and lead timing.
- Investment in Channel Expansion: Training and certifying O&P clinicians is a long-term growth lever but requires sustained operational support.
- Marketing Adaptability: Rapid response to social media platform changes is crucial to maintain lead flow and control acquisition costs.
- Manufacturing Capacity Alignment: Facility expansion aligns production capability with forecast demand, mitigating supply constraints.
Risks
Myomo faces ongoing risks related to payer reimbursement policies, particularly from Medicare Advantage and commercial insurers, which may delay or deny patient access. Marketing channel volatility, regulatory changes, and patient attrition in the sales pipeline also pose challenges. Execution risk exists in scaling new distribution channels and managing increased operating expenses.
Forward Outlook
For Q2 2025, Myomo guided revenue between $9.0 million and $9.5 million, reflecting a slight sequential decline due to early quarter lead generation disruptions. Management expects revenue growth acceleration in the second half of 2025, supported by improved marketing efficiency and pipeline expansion.
- Q2 revenue guidance: $9.0 million to $9.5 million, up 20% to 26% year-over-year
- Full-year 2025 revenue guidance: $50 million to $53 million, representing 54% to 66% growth over 2024
Management anticipates negative cash flow through Q3, with a return to positive operating cash flow by Q4 2025, driven by scaling revenues and operational leverage.
Takeaways
Myomo’s Q1 results validate its strategic focus on Medicare Part B commercialization and channel development, positioning it for meaningful growth despite external headwinds.
- Medicare Coverage Drives ASP and Volume Gains: The company’s ability to capitalize on Medicare Part B reimbursement is central to its revenue and margin expansion.
- Channel and Product Innovation Fuel Future Growth: Expansion of the O&P channel and new product introductions like MyoPro 2X enhance competitive positioning and market reach.
- Execution on Marketing and Payer Engagement Critical: Sustained improvements in lead generation and insurance authorization processes will be key to realizing the company’s growth targets.
Conclusion
Myomo’s first quarter showcased strong revenue growth driven by Medicare adoption and international expansion, offset by temporary marketing disruptions and reimbursement challenges. The company’s investments in product innovation, channel development, and payer engagement set the stage for accelerated growth and improved cash flow in the second half of 2025.
Industry Read-Through
Myomo’s experience underscores the growing importance of Medicare reimbursement pathways in enabling adoption of advanced medical robotics devices. The challenges with Medicare Advantage denials and social media marketing changes reflect broader industry headwinds impacting healthcare technology providers reliant on consumer lead generation and complex payer landscapes. The company’s proactive approach to channel expansion and payer negotiations offers a blueprint for others navigating similar dynamics in the wearable medical device sector.